The Numbers Work.
A validated financial model demonstrating that the VICP Trust Fund can absorb all COVID-19 vaccine injury claims while growing from $4.5 billion to $12.1 billion over 10 years — with a $537 million annual surplus.
Where the Money Comes From
Every vaccine dose administered in the U.S. carries an excise tax that funds the VICP Trust Fund. H.R. 5142 raises the rate from $0.75 to $2.20 per dose and adds new vaccines to the program.
Dose Volume Breakdown
Total Annual Inflows
Sources: HRSA Dose Distribution Table (2006–2024), CDC COVIDVaxView, CDC MMWR
Where the Money Goes
Annual outflows cover existing VICP claims, new COVID-19 claims (capacity-constrained), and claims from newly covered vaccines like RSV and Shingles.
Existing VICP
Bill raises death benefit and P&S caps from $250K → $600K + CPI. Most claims don't hit the cap — only ~20% of claims are affected.
COVID-19 Claims
10 masters (1,625 capacity) must handle 1,200 ongoing VICP + 218 new vaccine filings, leaving 207 slots for COVID claims.
New Vaccines
RSV is the largest new risk — FDA required a GBS warning on RSV vaccines in January 2025.
$537 Million Annual Surplus
The Trust Fund doesn't just survive adding COVID vaccines — it grows substantially every single year.
COVID claims represent only 8% of annual outflows ($30M of $373M)
New vaccine excise revenue (~$73M) exceeds new vaccine claims ($55M)
Processing constraints spread COVID liability over ~68 years at 10 masters — adding more masters accelerates this dramatically
Trust Fund Growth Trajectory
With CPI adjustments growing both inflows and outflows at roughly equal rates, the surplus remains stable year over year. The Trust Fund nearly triples.
Three Paths, Same Result: Solvency
Regardless of how COVID claims are prioritized against the existing backlog, the Trust Fund remains solvent under all scenarios.
COVID claims enter the queue immediately upon filing. Special masters process all claim types concurrently.
All three scenarios produce a Year 10 Trust Fund balance between $11.37B and $12.55B. The processing approach primarily affects claimant wait times, not program solvency.
Table Injury Bulk Settlement
The bill adds table injuries (myocarditis, GBS, TTS) with presumptive causation. These claims could be resolved through flat-rate administrative settlement without consuming special master time — dramatically reducing the backlog.
At 50% table injury eligibility with 20 masters, the entire COVID backlog clears in ~4 years. The Trust Fund never drops below $3.1B and recovers to $4.5B within ~2 years after clearing all claims. Bulk settlement front-loads cost but eliminates decades of processing.
What If We Process Everything as Fast as Possible?
30 masters, 65% approval rate, $500K average awards — the most aggressive scenario imaginable. Can the Trust Fund survive?
The Trust Fund never goes negative.
Low point: $2.52B at end of Year 4 (56% of starting balance). All COVID claims cleared by Year 5. Fund recovers to starting balance by Year 7 and reaches $6.80B by Year 10.
CICP's 1.4% Eligibility Rate Is Misleading
CICP denied 6,334 of 6,421 decided claims. But only 19.5% were denied on the actual merits of the case. The rest were procedural failures that VICP's structure directly solves.
75% of CICP decisions were procedural denials — missed deadlines and missing documentation. VICP directly addresses this with longer filing windows, attorney representation, and fee coverage.
Merits-only approval rate: 87 eligible out of 1,338 merits-based decisions = 6.5%. VICP's table injury presumptions and settlement culture (60% of awards are settlements) raise this substantially.
VICP Structural Advantages Over CICP
Every Number Has a Source
HRSA VICP Monthly Statistics Report
March 1, 2026
Petitions filed, adjudications, awards paid, dose distribution
View SourceFDA Safety Communication
January 2025
RSV vaccine GBS warning requirement for Abrysvo and Arexvy
View SourceZhao et al. (2022)
Journal of Law & Biosciences
Trust Fund interest income analysis and historical data
View SourceCRS IF12625 & IF13011
Judiciary Budget Requests
Office of Special Masters budget: $10M/yr (8 masters) → ~$1.25M per master
View SourceH.R. 5142 — Full Bill Text
118th Congress
Vaccine Injury Compensation Modernization Act — excise, special masters, COVID coverage
View Source42 U.S.C. 300aa-12
U.S. Code
Statutory salary caps for special masters (Executive Schedule Level IV/V)
View SourceThe Math Is Clear.
The Question Is Political Will.
The VICP Trust Fund can handle COVID vaccine injury claims while growing for decades. Americans injured by COVID vaccines deserve the same fair process as those injured by routine vaccines.